Max Healthcare Shares Jump 6% After Citi Initiates Buy Rating; Check the Target Price

Synopsis: The share of this company jumped 6 percent after a ‘Buy’ rating, driven by attractive valuations, strong outlook, 21 percent upside potential, and a sharp volume surge of nearly 394 percent.

The shares of this company, which is one of India’s largest private hospital chains, operating over 22 facilities and 5,000+ beds primarily across North and West India, gained investor traction today after brokerage bullish stance.

With a market capitalization of Rs 1,05,417 crore, Max Healthcare Institute Ltd’s shares on Thursday made a day high of Rs 1,088 per share, up by 6 percent from its previous day’s close price of Rs 1,026.15 per share. The share of the company gave a return of 331 percent over the last five years.

Factors that might be fueling the stock rally today

Citi turns positive with ‘Buy’ rating: Max Healthcare came into focus after Citi initiated a ‘Buy’ call on the stock with a target price of Rs 1,240 per share, indicating potential 21 percent upside from the previous close. The brokerage view has improved sentiment around the stock, triggering buying interest during the session.

Valuation comfort after recent correction: Citi highlighted that the stock is down around 18 percent from the 52-week high, which has brought valuations back in line with historical averages. This correction has improved the risk-reward profile, making the stock more attractive from a medium-term perspective.

Strong earnings outlook with execution risks: The brokerage expects Max Healthcare to deliver a 20 percent EBITDA CAGR over FY26–FY30, supported by steady demand and operating leverage. Revenue growth is projected at 15 percent in FY27, with further acceleration expected in FY28. However, Citi flagged execution delays as a key risk to the outlook.

Volume Surge: The stock saw a sharp rise in activity, with trading volumes increasing from an hourly average of around 277,000 shares to nearly 1.4 million shares. This marks a strong jump of about 394 percent, indicating robust investor participation and strong momentum in the counter, and the stock has already crossed its daily average volume of 3.75 M, with the first 4 hours of trading volume being 5M.

Technical Conditions: From a technical perspective, the stock continued to trade above its key moving averages, including the 50-EMA and 200-EMA. This sustained positioning above important trend indicators reflects a strong underlying uptrend and healthy price momentum.

Multiple avenues for future growth

Max Healthcare’s growth outlook is supported by strong financial strength, with operating cash flow of Rs 1,541 crore in FY26, net debt of Rs 1,908 crore, and a healthy ROCE of around 23 percent, enabling steady expansion while maintaining balance sheet flexibility.

The company’s growth is anchored in optimising existing infrastructure through better speciality mix, higher utilization, improved efficiency, and stronger payor mix, which helps lift returns without requiring large incremental capital.

Alongside this, Max Healthcare is expanding capacity significantly through multiple routes, including ~2,000 beds via brownfield projects, asset-light O&M and lease models, strategic M&A with strong turnaround capability, and greenfield hospitals in high-potential locations like Gurgaon and Lucknow, supporting near doubling of capacity over the medium term.

About the Company

Max Healthcare Institute Limited is primarily engaged in the providing healthcare services through primary care clinics, multi-speciality hospitals / medical centres and super-speciality hospitals providing operation and management, medical services, clinical, radiology, pathology services and related healthcare services.

Financial Highlights: The revenue from operations grew by 12 percent to Rs 2,143 crore in Q4 FY26 from Rs 1,910 crore in Q4 FY25, and EBIDT grew by 19 percent to Rs 606 crore in Q4 FY26 from Rs 512 crore in Q4 FY25. This was accompanied by a net profit growth of 7 percent to Rs 342 crore in Q4 FY26 from Rs 319 crore in Q4 FY25, resulting in an EPS growth of 7 percent to Rs 3.52 per share in Q4 FY26 from Rs 3.28 per share in Q4 FY25.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Max Healthcare Shares Jump 6% After Citi Initiates Buy Rating; Check the Target Price appeared first on Trade Brains.